Related Experiment Video

Updated: Nov 22, 2025

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

11.1K

miRNA as Regulators of Prostate Carcinogenesis and Endocrine and Chemoresistance

Zoran Culig1

  • 1Experimental Urology, Department of Urology, Medical University of Innsbruck, Anichstrasse 35, A-6020 Innsbruck, Austria.

Current Cancer Drug Targets
|January 11, 2021
PubMed

Insights

MicroRNAs (miRNAs) play a crucial role in advanced prostate cancer progression and treatment resistance. Targeting specific miRNAs offers potential for improved therapeutic strategies and biomarkers in prostate cancer management.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Advanced prostate cancer has increasing therapeutic options, yet castration-resistant disease remains challenging.
  • Small non-coding microRNAs (miRNAs) regulate critical cellular events in cancer, influencing disease progression and treatment response.
  • miRNAs are implicated in prostate cancer development, progression, and potential as biomarkers.

Purpose of the Study:

  • To explore the role of microRNAs (miRNAs) in the regulation of cellular events in prostate cancer.
  • To investigate the potential of miRNAs as biomarkers and therapeutic targets in advanced and castration-resistant prostate cancer.
  • To understand how miRNA expression influences androgen independence, proliferation, apoptosis, migration, invasion, and epithelial-to-mesenchymal transition.

Main Methods:

  • Analysis of miRNA expression patterns in prostate cancer.
  • Investigating the functional impact of miRNA overexpression or suppression on cancer cell behavior.
  • Examining the relationship between miRNA activity and signaling pathways (e.g., EGFR, MAPK).
  • Evaluating the role of miRNAs in regulating chemosensitivity and cellular stemness.

Main Results:

  • Overexpression of certain miRNAs can promote androgen independence and prostate cancer progression.
  • Diminished expression of tumor-suppressive miRNAs enhances proliferation, reduces apoptosis, and increases migration/invasion.
  • miRNAs are involved in regulating chemosensitivity, with experimental overexpression inhibiting stemness and epithelial-to-mesenchymal transition in chemoresistant cells.
  • Reduced tumor-suppressive miRNA levels can lead to hyperactivity of signaling pathways like EGFR and MAPK.

Conclusions:

  • MicroRNAs are key regulators of prostate cancer progression, influencing androgen sensitivity, metastasis, and treatment response.
  • Dysregulated miRNA expression, particularly the loss of tumor-suppressive miRNAs, contributes significantly to prostate cancer aggressiveness.
  • miRNAs hold promise as biomarkers and therapeutic targets, but novel delivery methods are needed to optimize their clinical utility in prostate cancer treatment.
Keywords:
Prostate cancerandrogenic regulationchemotherapymiRNAoncogenestumor suppressors

More Related Videos

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR08:30

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR

Published on: May 16, 2012

24.8K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.0K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.3K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.4K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.4K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.1K
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.7K